Market open
ADC Therapeutics/$ADCT
ADC Therapeutics shares are trading higher after the company presented positive clinical trial data and reported Q1 revenue above estimates.
36 minutes ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ADC Therapeutics
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Ticker
$ADCT
Sector
Trading on
NYSE
Industry
Biotechnology
Headquarters
Epalinges, Switzerland
Employees
264
ISIN
CH0499880968
Website
ADC Therapeutics Metrics
BasicAdvanced
$131M
-
-$1.62
1.56
-
Price and volume
Market cap
$131M
Beta
1.56
52-week high
$4.32
52-week low
$1.05
Average daily volume
293K
Financial strength
Current ratio
3.82
Quick ratio
3.37
Long term debt to equity
-217.98
Total debt to equity
-218.657
Interest coverage (TTM)
-2.60%
Management effectiveness
Return on assets (TTM)
-24.13%
Return on equity (TTM)
89.97%
Valuation
Price to revenue (TTM)
1.811
Price to book
-0.64
Price to tangible book (TTM)
-0.64
Price to free cash flow (TTM)
-1.028
Growth
Revenue change (TTM)
1.84%
Earnings per share change (TTM)
-44.70%
3-year revenue growth (CAGR)
27.82%
3-year earnings per share growth (CAGR)
-18.46%
What the Analysts think about ADC Therapeutics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ADC Therapeutics stock.
ADC Therapeutics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ADC Therapeutics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ADC Therapeutics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ADC Therapeutics stock?
ADC Therapeutics (ADCT) has a market cap of $131M as of May 14, 2025.
What is the P/E ratio for ADC Therapeutics stock?
The price to earnings (P/E) ratio for ADC Therapeutics (ADCT) stock is 0 as of May 14, 2025.
Does ADC Therapeutics stock pay dividends?
No, ADC Therapeutics (ADCT) stock does not pay dividends to its shareholders as of May 14, 2025.
When is the next ADC Therapeutics dividend payment date?
ADC Therapeutics (ADCT) stock does not pay dividends to its shareholders.
What is the beta indicator for ADC Therapeutics?
ADC Therapeutics (ADCT) has a beta rating of 1.56. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.